Triangle Coactinon
Executive Summary
Emivirine shows higher than anticipated metabolic interactions with Warner-Lambert's Viracept (nelfinavir), allowing unblinding of Triangle's Phase III study of emivirine in combination with a three-drug regimen of two nucleosides and a protease inhibitor after 24 weeks. The results may delay the NDA submission for Coactinon, the company said